chr17-44372391-CA-C
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM4PP4_StrongPM2_SupportingPM3_Supporting
This summary comes from the ClinGen Evidence Repository: The NM_000419.5(ITGA2B):c.3092del (p.Leu1031ArgfsTer?) variant causes a frameshift and subsequent stop loss. This results in the addition of 90 amino acids to the ITGA2B protein, beyond the cytoplasmic domain (PM4). The variant is absent from gnomAD v2.1.1 (PM2_Supporting). At least one patient (Patient GT11 in PMID:25373348) with this variant displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia. Additionally, αIIbβ3 surface expression was reduced between 5% and 20% and function was pathological, as measured by flow cytometry (PP4_strong). This patient is compound heterozygous for the maternal c.3092del variant and Leu214Pro (classified Pathogenic by the PD-EP), without confirmation of trans phase (PM3_supporting). In summary this variant meets criteria to be classified as Likely Pathogenic for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PP4_strong, PM2_supporting, PM3_supporting, PM4. (VCEP specifications version 2; date of approval xx/xx/xxxx) LINK:https://erepo.genome.network/evrepo/ui/classification/CA915940323/MONDO:0100326/011
Frequency
Consequence
NM_000419.5 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ITGA2B | NM_000419.5 | c.3092del | p.Leu1031ArgfsTer? | frameshift_variant | 30/30 | ENST00000262407.6 | |
ITGA2B | XM_011524749.2 | c.3143del | p.Leu1048ArgfsTer? | frameshift_variant | 29/29 | ||
ITGA2B | XM_011524750.2 | c.3128del | p.Leu1043ArgfsTer? | frameshift_variant | 29/29 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ITGA2B | ENST00000262407.6 | c.3092del | p.Leu1031ArgfsTer? | frameshift_variant | 30/30 | 1 | NM_000419.5 | P1 | |
ITGA2B | ENST00000648408.1 | c.2406del | p.Leu803ArgfsTer? | frameshift_variant | 25/25 | ||||
ITGA2B | ENST00000587295.5 | c.285del | p.Leu96ArgfsTer? | frameshift_variant | 3/3 | 3 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461872Hom.: 0 Cov.: 30 AF XY: 0.00000275 AC XY: 2AN XY: 727244
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Glanzmann thrombasthenia Pathogenic:1
Likely pathogenic, reviewed by expert panel | curation | ClinGen Platelet Disorders Variant Curation Expert Panel, ClinGen | Dec 02, 2021 | The NM_000419.5(ITGA2B):c.3092del (p.Leu1031ArgfsTer?) variant causes a frameshift and subsequent stop loss. This results in the addition of 90 amino acids to the ITGA2B protein, beyond the cytoplasmic domain (PM4). The variant is absent from gnomAD v2.1.1 (PM2_Supporting). At least one patient (Patient GT11 in PMID:25373348) with this variant displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia. Additionally, alphaIIbbeta3 surface expression was reduced between 5% and 20% and function was pathological, as measured by flow cytometry (PP4_strong). This patient is compound heterozygous for the maternal c.3092del variant and Leu214Pro (classified Pathogenic by the PD-EP), without confirmation of trans phase (PM3_supporting). In summary this variant meets criteria to be classified as Likely Pathogenic for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PP4_strong, PM2_supporting, PM3_supporting, PM4. (VCEP specifications version 2; date of approval xx/xx/xxxx) - |
Glanzmann thrombasthenia 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 19, 2024 | Variant summary: ITGA2B c.3092delT (p.Leu1031ArgfsX70+) causes a frameshift which results in an extension of the protein. This variant results in the addition of 90 amino acids to the ITGA2B protein, beyond the cytoplasmic domain. The variant was absent in 251356 control chromosomes. c.3092delT has been reported in the literature in at-least two individuals affected with Glanzmann thrombasthenia, in each case, it was at a compound heterozygous along with a different pathogenic missense (example, Sandrock-Lang_2015, Sharma_2021). These data indicate that the variant may be associated with disease. Additionally, a similar extension variant c.3091delC variant causes a frameshift Leu1031TrpfsTer97 and subsequent stop loss, also adds 90 amino acids to the ITGA2B protein, and was evaluated Likely Pathogenic per ClinGen Platelet Disorders Variant Curation Expert Panel (ClinVar ID 1879040). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 25373348, 34267460). ClinVar contains an entry for this variant (Variation ID: 1691488). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.